Literature DB >> 22999863

Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response.

Cheng Chen1, Yu Shen, Qiu-Xia Qu, Xu-Qin Chen, Xue-Guang Zhang, Jian-An Huang.   

Abstract

Macrophages are the prominent components of solid tumors and have complex dual functions in their interaction with cancer cells. Strong evidence suggests that TAM is a part of inflammatory circuits that promote tumor progression. B7-homologue 3 (B7-H3), a recently identified homologue of B7.1/2 (CD80/86), has been described to exert co-stimulatory and immune regulatory functions. Here, we showed that a fraction of macrophages in tumor stroma expressed surface B7-H3 molecule. Normal macrophages, which did not express B7-H3, would be induced expressing B7-H3 molecule when culturing with tumor cell. Although a lung cancer cell line constitutively expressed B7-H3 mRNA and protein in plasma, primary tumor cell isolated from the transplanted lung carcinoma model expressed B7-H3 on the surface. Interestingly, in transplanted lung carcinoma model, the expression of membrane-bound B7-H3 in tumor cells was increased as prolonging of tumor transformation. In support, IL-10 released from TAM could stimulate cancer cell expression of membrane bound B7-H3. Furthermore, Lung cancer and TAM-related B7-H3 was identified as a strong inhibitor of T-cell effect and influenced the outcome of T cell immune response. In conclusion, TAM-tumor cell interaction-induced membrane-bound B7-H3 represents a novel immune escape mechanism which links the pro-inflammatory response to immune tolerance in the tumor milieu.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22999863     DOI: 10.1016/j.yexcr.2012.09.006

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  38 in total

1.  The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers.

Authors:  Hideki Ujiie; Kyuichi Kadota; Jun-Ichi Nitadori; Joachim G Aerts; Kaitlin M Woo; Camelia S Sima; William D Travis; David R Jones; Lee M Krug; Prasad S Adusumilli
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

2.  Breast Cancer Detection by B7-H3-Targeted Ultrasound Molecular Imaging.

Authors:  Sunitha V Bachawal; Kristin C Jensen; Katheryne E Wilson; Lu Tian; Amelie M Lutz; Jürgen K Willmann
Journal:  Cancer Res       Date:  2015-04-21       Impact factor: 12.701

Review 3.  B7-H3 role in the immune landscape of cancer.

Authors:  Jose R Castellanos; Ian J Purvis; Collin M Labak; Maheedhara R Guda; Andrew J Tsung; Kiran K Velpula; Swapna Asuthkar
Journal:  Am J Clin Exp Immunol       Date:  2017-06-15

4.  Ablation of B7-H3 but Not B7-H4 Results in Highly Increased Tumor Burden in a Murine Model of Spontaneous Prostate Cancer.

Authors:  Katharina Kreymborg; Stefan Haak; Rajmohan Murali; Joyce Wei; Rebecca Waitz; Georg Gasteiger; Peter A Savage; Marcel R M van den Brink; James P Allison
Journal:  Cancer Immunol Res       Date:  2015-06-29       Impact factor: 11.151

5.  Relationship Between Serum B7-H3 Levels and Prognosis of Congenital Heart Disease in Children.

Authors:  Rufang Zhang; Jin Gong; Shouqing Wang; Li Shen; Yewei Xie; Xiaobing Li
Journal:  Pediatr Cardiol       Date:  2018-10-17       Impact factor: 1.655

Review 6.  The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.

Authors:  Murali Janakiram; Urvi A Shah; Weifeng Liu; Aimin Zhao; Mark P Schoenberg; Xingxing Zang
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

7.  Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone.

Authors:  Ahmad Al-Sukaini; Francis J Hornicek; Zachary S Peacock; Leonard B Kaban; Soldano Ferrone; Joseph H Schwab
Journal:  Clin Orthop Relat Res       Date:  2017-07-19       Impact factor: 4.176

8.  Lipoxin A4 inhibits NF-κB activation and cell cycle progression in RAW264.7 cells.

Authors:  Yong-Hong Huang; Hong-Mei Wang; Zhen-Yu Cai; Fang-Yun Xu; Xiao-Yan Zhou
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

9.  Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.

Authors:  Elodie Picarda; Kim C Ohaegbulam; Xingxing Zang
Journal:  Clin Cancer Res       Date:  2016-05-20       Impact factor: 12.531

10.  Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.

Authors:  John de Groot; Marta Penas-Prado; Kristin Alfaro-Munoz; Kathy Hunter; Be Lian Pei; Barbara O'Brien; Shiao-Pei Weathers; Monica Loghin; Carlos Kamiya Matsouka; W K Alfred Yung; Jacob Mandel; Jimin Wu; Ying Yuan; Shouhao Zhou; Gregory N Fuller; Jason Huse; Ganesh Rao; Jeffrey S Weinberg; Sujit S Prabhu; Ian E McCutcheon; Frederick F Lang; Sherise D Ferguson; Raymond Sawaya; Rivka Colen; Shalini S Yadav; Jorge Blando; Luis Vence; James Allison; Padmanee Sharma; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2020-04-15       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.